474 related articles for article (PubMed ID: 10389938)
1. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
[TBL] [Abstract][Full Text] [Related]
2. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers.
Gillesby BE; Zacharewski TR
Breast Cancer Res Treat; 1999 Aug; 56(3):253-65. PubMed ID: 10573116
[TBL] [Abstract][Full Text] [Related]
3. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
[TBL] [Abstract][Full Text] [Related]
4. Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines.
Tong D; Czerwenka K; Sedlak J; Schneeberger C; Schiebel I; Concin N; Leodolter S; Zeillinger R
Breast Cancer Res Treat; 1999 Jul; 56(1):91-7. PubMed ID: 10517346
[TBL] [Abstract][Full Text] [Related]
5. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-alpha mRNA in primary breast cancer: relationship to estrogen and progesterone receptor proteins and other prognostic factors.
Chearskul S; Bhothisuwan K; Churintrapun M; Semprasert N; Onreabroi S
Asian Pac J Allergy Immunol; 2002 Mar; 20(1):13-21. PubMed ID: 12125913
[TBL] [Abstract][Full Text] [Related]
7. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ER, PR, MIB-1, pS2, and nuclear grade in FNA specimens of cT1 breast carcinomas: clinicopathological correlation.
Angelidou E; Politi E; Sotiropoulou G; Poulianou E; Koutselini H
Diagn Cytopathol; 2006 Aug; 34(8):547-52. PubMed ID: 16850494
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
[TBL] [Abstract][Full Text] [Related]
10. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
11. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
Lau KM; LaSpina M; Long J; Ho SM
Cancer Res; 2000 Jun; 60(12):3175-82. PubMed ID: 10866308
[TBL] [Abstract][Full Text] [Related]
12. Expression of pS2 protein and estrogen and progesterone receptor status in breast cancer.
Ioakim-Liossi A; Karakitsos P; Markopoulos C; Aroni K; Delivelioti K; Gogas J; Kyrkou K
Acta Cytol; 1997; 41(3):713-6. PubMed ID: 9167689
[TBL] [Abstract][Full Text] [Related]
13. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.
Bieche I; Parfait B; Le Doussal V; Olivi M; Rio MC; Lidereau R; Vidaud M
Cancer Res; 2001 Feb; 61(4):1652-8. PubMed ID: 11245479
[TBL] [Abstract][Full Text] [Related]
14. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
Eppenberger U; Kueng W; Schlaeppi JM; Roesel JL; Benz C; Mueller H; Matter A; Zuber M; Luescher K; Litschgi M; Schmitt M; Foekens JA; Eppenberger-Castori S
J Clin Oncol; 1998 Sep; 16(9):3129-36. PubMed ID: 9738585
[TBL] [Abstract][Full Text] [Related]
15. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
Leissner P; Verjat T; Bachelot T; Paye M; Krause A; Puisieux A; Mougin B
BMC Cancer; 2006 Aug; 6():216. PubMed ID: 16945123
[TBL] [Abstract][Full Text] [Related]
17. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.
Bièche I; Parfait B; Laurendeau I; Girault I; Vidaud M; Lidereau R
Oncogene; 2001 Dec; 20(56):8109-15. PubMed ID: 11781824
[TBL] [Abstract][Full Text] [Related]
18. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of pS2 expression during the development of adenocarcinomas but not squamous cell carcinomas of the uterine cervix, independently of expression of c-jun or oestrogen and progesterone receptors.
Saegusa M; Hashimura M; Hara A; Okayasu I
J Pathol; 2000 Apr; 190(5):554-63. PubMed ID: 10727981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]